224 related articles for article (PubMed ID: 38170178)
61. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
Fivenson DP; Hanson CA; Nickoloff BJ
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
[TBL] [Abstract][Full Text] [Related]
62. Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication.
Dummer R; Döbbeling U; Geertsen R; Willers J; Burg G; Pavlovic J
Blood; 2001 Jan; 97(2):523-7. PubMed ID: 11154232
[TBL] [Abstract][Full Text] [Related]
63. Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody.
Numata T; Nagatani T; Shirai K; Maeda T; Mae K; Nakasu M; Saito M; Usuda T; Tsuboi R; Okubo Y
Clin Exp Dermatol; 2018 Apr; 43(3):281-285. PubMed ID: 29327377
[TBL] [Abstract][Full Text] [Related]
64. Cell surface molecules involved in early events in T-cell mitogenic stimulation by staphylococcal enterotoxins.
Vroegop SM; Buxser SE
Infect Immun; 1989 Jun; 57(6):1816-24. PubMed ID: 2785962
[TBL] [Abstract][Full Text] [Related]
65. T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells.
Fleischer B; Schrezenmeier H
J Exp Med; 1988 May; 167(5):1697-707. PubMed ID: 3259256
[TBL] [Abstract][Full Text] [Related]
66. Mechanism of Staphylococcus aureus exotoxin A inhibition of Ig production by human B cells.
Moseley AB; Huston DP
J Immunol; 1991 Feb; 146(3):826-32. PubMed ID: 1988499
[TBL] [Abstract][Full Text] [Related]
67. Staphylococcal enterotoxin-mediated human T-T cell interactions.
Koning F; Rust C
J Immunol; 1992 Jul; 149(1):317-22. PubMed ID: 1535087
[TBL] [Abstract][Full Text] [Related]
68. Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
Karthik S; Sankar R; Varunkumar K; Anusha C; Ravikumar V
Biomed Pharmacother; 2015 Feb; 69():337-44. PubMed ID: 25661379
[TBL] [Abstract][Full Text] [Related]
69. Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma.
Peru S; Prochazkova-Carlotti M; Cherrier F; Velazquez J; Richard E; Idrissi Y; Cappellen D; Azzi-Martin L; Pham-Ledard A; Beylot-Barry M; Merlio JP; Poglio S
J Invest Dermatol; 2022 Dec; 142(12):3243-3252.e10. PubMed ID: 35850209
[TBL] [Abstract][Full Text] [Related]
70. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
71. TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL.
Kremer KN; Dinkel BA; Sterner RM; Osborne DG; Jevremovic D; Hedin KE
Blood; 2017 Aug; 130(8):982-994. PubMed ID: 28694325
[TBL] [Abstract][Full Text] [Related]
72. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
Eriksen KW; Kaltoft K; Mikkelsen G; Nielsen M; Zhang Q; Geisler C; Nissen MH; Röpke C; Wasik MA; Odum N
Leukemia; 2001 May; 15(5):787-93. PubMed ID: 11368440
[TBL] [Abstract][Full Text] [Related]
73. Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death.
Klemke CD; Brenner D; Weiss EM; Schmidt M; Leverkus M; Gülow K; Krammer PH
Cancer Res; 2009 May; 69(10):4175-83. PubMed ID: 19435902
[TBL] [Abstract][Full Text] [Related]
74. Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatment.
Borcherding N; Severson KJ; Henderson N; Ortolan LS; Rosenthal AC; Bellizzi AM; Liu V; Link BK; Mangold AR; Jabbari A
Blood Adv; 2023 Feb; 7(3):321-335. PubMed ID: 35390145
[TBL] [Abstract][Full Text] [Related]
75. The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion.
Zhao L; Hsiao T; Stonesifer C; Daniels J; Garcia-Saleem TJ; Choi J; Geskin L; Rook AH; Wood GS
J Invest Dermatol; 2022 Dec; 142(12):3253-3261.e4. PubMed ID: 35787399
[TBL] [Abstract][Full Text] [Related]
76. Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma.
Gallardo F; Bertran J; López-Arribillaga E; González J; Menéndez S; Sánchez I; Colomo L; Iglesias M; Garrido M; Santamaría-Babí LF; Torres F; Pujol RM; Bigas A; Espinosa L
Leukemia; 2018 Oct; 32(10):2211-2223. PubMed ID: 29511289
[TBL] [Abstract][Full Text] [Related]
77. Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins.
Tokura Y; Heald PW; Yan SL; Edelson RL
J Invest Dermatol; 1992 Jan; 98(1):33-7. PubMed ID: 1728639
[TBL] [Abstract][Full Text] [Related]
78. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
[TBL] [Abstract][Full Text] [Related]
79. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
[TBL] [Abstract][Full Text] [Related]
80. Molecular advances in cutaneous T-cell lymphoma.
Bastidas Torres AN; Najidh S; Tensen CP; Vermeer MH
Semin Cutan Med Surg; 2018 Mar; 37(1):81-86. PubMed ID: 29719024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
